Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Bone Therapeutics SA
  6. News
  7. Summary
    BOTHE   BE0974280126


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bone Therapeutics : 11/29/21 - Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB

11/29/2021 | 01:10am EST
Gosselies, Belgium, 29 November 2021, 7:00 am CET - BONE THERAPEUTICS
(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd ("Link Health"), today announce the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics' allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is separate and independent from the existing license agreement signed on October 5, 2020, for the rights to develop, manufacture and commercialize ALLOB in China for Pregene, and in Hong Kong, Macau, Singapore, Taiwan, Thailand and South Korea for Link Health. Bone Therapeutics will continue to work closely in partnership with Link Health and Pregene on all development activities. Link Health will be responsible for all future development, including the ongoing ALLOB TF2 Phase IIb trial and costs related to development, process development (scale up) and manufacturing of ALLOB. The deal will have no immediate direct cash impact, other than support of all development costs, since no upfront payment is foreseen, however, Bone Therapeutics will receive commercial milestone payments of up to €60 million in total and tiered royalties on net sales of up to 25%. "The existing collaboration between Bone Therapeutics, Link Health and Pregene for the development of ALLOB in Asia has progressed swiftly and fully in line with the anticipated schedule. Bone Therapeutics expanding its collaboration with Link Health will allow for the development and potential availability of ALLOB globally for the benefit of patients with high orthopedic unmet medical needs," said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. "This deal now enables Bone Therapeutics to concentrate resources and focus more fully on its iMSC platform. We are now utilizing our extensive cell therapy expertise to develop cell and gene therapy products that have strong anti-inflammatory and immunomodulatory properties, for the treatment of acute life-threatening diseases."
"Link Health has now broadened its therapeutic portfolio to address orthopedic unmet medical needs, aiming to be a global leader in this area. We have already several assets in clinical trial and next generation drug-material combo will also part of our efforts. For ALLOB, we believe that the evidence that Bone Therapeutics has already generated supports its potential clinical value for patients in various indications including spinal fusion and difficult fractures." saidYan Song, PhD, Chief Executive Officer of Link Health. "Our extended collaboration with Bone Therapeutics will further support the global development of ALLOB. This will enable us to progress in delivering novel disease modifying solution for unmet medical needs for orthopedic patients worldwide." ALLOB is currently being evaluated in a randomized, double-blind, placebo-controlled Phase IIb study in patients with high-risk tibial fractures. This study will assess and compare against placebo, in association with standard of care stabilization surgery, the potential for ALLOB to accelerate fracture healing after 3-months follow-up and prevent late-stage complications. ALLOB will be applied by a single percutaneous injection 24-96 hours post-definitive reduction surgery in patients with fresh tibial fractures at risk of delayed or non-union.


Bone Therapeutics SA published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 06:09:08 UTC.

ę Publicnow 2021
01/19Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook
2021BONE THERAPEUTICS - Transparency notification received from S.R.I.W. SA and Sofipole SA..
2021BONE THERAPEUTICS SA : Transparency notification received from S.R.I.W. SA and Sofipôle SA
2021BONE THERAPEUTICS SA : Crossing thresholds
2021Nyenburgh Raises Bone Therapeutics Stake to Almost 6%
2021BONE THERAPEUTICS SA : Transparency notification received from Nyenburgh Holding NV
2021BONE THERAPEUTICS SA : Monthly statement on outstanding equity shares and voting rights
2021BONE THERAPEUTICS SA : Monthly statement on outstanding equity shares and voting rights
2021Bone Therapeutics Raises $4 Million To Advance Lead Orthopedic Asset
2021Bone Therapeutics announces closing of private placement
More news
Analyst Recommendations on BONE THERAPEUTICS SA
More recommendations
Sales 2021 20,8 M 23,5 M 23,5 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 12,3 M 13,9 M 13,9 M
Capi. / Sales 2021 0,59x
Capi. / Sales 2022 4,56x
Nbr of Employees 30
Free-Float 82,2%
Duration : Period :
Bone Therapeutics SA Technical Analysis Chart | BOTHE | BE0974280126 | MarketScreener
Technical analysis trends BONE THERAPEUTICS SA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,58 €
Average target price 2,50 €
Spread / Average Target 333%
Managers and Directors
Miguel Forte Chief Executive Officer & Director
Lieve Creten Chief Financial Officer
Baron Jean StÚphenne Chairman
Anthony Ting Chief Scientific Officer
Anne Leselbaum Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643